ArticleFrontiers in pharmacology2025
Baicalein ameliorates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and regulating gut microbiota.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Multi-Dimensional Mechanisms and Druggability Optimization Strategies of Active Ingredients from Traditional Chinese Medicine in the Treatment of Ulcerative Colitis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Research Progress and Prospects of Flavonoids in the Treatment of Diseases by Regulating Autophagy: A Narrative Review.Molecules (Basel, Switzerland) · 2026Review
- Article
- Molecular Mechanisms and Therapeutic Potential of Baicalein in Acute Pancreatitis: A Comprehensive Review.Biomolecules · 2026Review
- Review
- Therapeutic Agents Targeting the Nrf2 Signaling Pathway to Combat Oxidative Stress and Intestinal Inflammation in Veterinary and Translational Medicine.Veterinary sciences · 2025Review
- Article
- Immune modulation in inflammatory bowel disease: therapeutic promise of baicalein.Frontiers in pharmacology · 2025Review
- Preparation, immunological and pharmacological effects of flavonoids in Scutellariae radix: a review.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a nonspecific inflammatory disease. Baicalein has potential value in treating UC, but its mechanism is unclear. This study aims to evaluate the protective effects of baicalein on dextran sodium sulfate (DSS)-induced UC mice. The UC model was established by 4% DSS solution for 7 days. Treatments included baicalein (10 mg/kg, 20 mg/kg) and sulfasalazine (200 mg/kg) via oral gavage. Colonic damage was assessed through body weight, disease activity index (DAI), histopathology (H&E staining) and colon length. Inflammatory cytokines were measured by ELISA, while oxidative stress markers and iron content were analyzed by colorimetric assays. Protein expression was evaluated by Western blot, and gene levels by RT-qPCR. Intestinal microbiota changes were characterized using 16S rRNA gene sequencing. Results demonstrated that Baicalein ameliorated UC mice, particularly in high-dose of baicalein group. After baicalein treatment, the proinflammatory cytokines (TNF-α, IL-1β), and anti-inflammatory cytokine (IL-10) has decreased. Additionally, high-dose of baicalein strongly reversed oxidative stress alterations caused by DSS, as evidenced by Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.